GILD logo

Gilead Sciences, Inc.

GILD
Healthcare|Drug Manufacturers - General|US
$166.89
-0.68 (-0.41%)
DCF Value
$137.19
Cash / Share
$5.18

Analyst Consensus

Buy58 analysts
Strong Buy
0
Buy
38
Hold
19
Sell
1
Strong Sell
0
Consensus Target
$165.38
Implied Upside
-0.9%
Low Target
$126.00
High Target
$196.00

Price Target Trend

Last Month
$182.00
7 targets · +9% vs price
Last Quarter
$173.30
10 targets · +4% vs price
Last Year
$157.20
51 targets · -6% vs price
All Time
$120.59
114 targets · -28% vs price

Rating Trend

Dec 25
21 buy · 8 hold · 0 sell
Jan 26
22 buy · 8 hold · 1 sell
Feb 26
22 buy · 7 hold · 1 sell
Mar 26
23 buy · 8 hold · 1 sell
Apr 26
23 buy · 8 hold · 0 sell
May 26
24 buy · 8 hold · 0 sell
Jun 26
24 buy · 7 hold · 0 sell
Jul 26
23 buy · 7 hold · 0 sell
Aug 26
22 buy · 7 hold · 1 sell
Sep 26
22 buy · 6 hold · 1 sell
Oct 26
22 buy · 5 hold · 1 sell
Nov 26
22 buy · 5 hold · 1 sell

Recent Price Targets

DateFirmAnalystTargetPrice ThenSource
Nov 4, 2026JefferiesAkash Tewari$196.00(+17%)$167.47StreetInsider
Nov 2, 2026BernsteinCourtney Breen$175.00(+5%)$167.33StreetInsider
Oct 30, 2026UBSMichael Yee$195.00(+14%)$170.95StreetInsider
Oct 30, 2026Needham$175.00(+6%)$165.61StreetInsider
Oct 30, 2026BMO CapitalEvan David Seigerman$184.00(+11%)$165.61StreetInsider
Oct 23, 2026JefferiesAkash Tewari$185.00(+18%)$157.19StreetInsider
Oct 12, 2026Raymond James$164.00(+8%)$151.17StreetInsider
Oct 8, 2026RBC CapitalBrian Abrahams$126.00(-13%)$145.64TheFly
Oct 7, 2026Truist Financial$158.00(+7%)$147.53TheFly
Sep 10, 2026HSBCMorten Herholdt$175.00(+20%)$145.65TheFly
Aug 5, 2026Truist Financial$150.00(+13%)$132.75TheFly
Aug 5, 2026RBC Capital$123.00(-9%)$135.25TheFly
Jul 29, 2026Barclays$145.00(+8%)$134.32TheFly
Jul 27, 2026Morgan Stanley$165.00(+26%)$131.23TheFly
Jul 20, 2026Leerink PartnersDaina Graybosch$127.00(-5%)$133.21TheFly
Jul 8, 2026Morgan Stanley$166.00(+22%)$136.36TheFly
Jul 7, 2026RBC CapitalBrian Abrahams$120.00(-7%)$129.61TheFly
Jul 6, 2026HSBCRajesh Kumar$155.00(+18%)$131.27StreetInsider
Jun 1, 2026RBC CapitalBrian Abrahams$122.00(-9%)$134.43StreetInsider
May 20, 2026Maxim GroupMichael Okunewitch$165.00(+26%)$130.55TheFly

Recent Rating Actions

FirmActionRatingDate
NeedhammaintainBuyOct 30, 2026
Cantor FitzgeraldmaintainOverweightOct 30, 2026
JP MorganmaintainOverweightOct 30, 2026
CitigroupmaintainBuyOct 30, 2026
ScotiabankmaintainSector OutperformOct 30, 2026
TD CowenmaintainBuyOct 30, 2026
Morgan StanleymaintainOverweightOct 30, 2026
Wells FargomaintainOverweightOct 30, 2026
Truist SecuritiesmaintainBuyOct 30, 2026
RBC CapitalmaintainSector PerformOct 30, 2026
UBSmaintainBuyOct 30, 2026
B of A SecuritiesmaintainBuyOct 20, 2026
RBC CapitalmaintainSector PerformOct 8, 2026
Cantor FitzgeraldmaintainOverweightOct 8, 2026
Morgan StanleymaintainOverweightOct 7, 2026
JP MorganmaintainOverweightOct 7, 2026
Truist SecuritiesmaintainBuyOct 7, 2026
HSBCmaintainBuySep 10, 2026
RBC CapitalmaintainSector PerformAug 5, 2026
NeedhammaintainBuyAug 5, 2026
Cantor FitzgeraldmaintainOverweightAug 5, 2026
BarclaysmaintainEqual WeightJul 29, 2026
Morgan StanleymaintainOverweightJul 27, 2026
Leerink PartnersdowngradeOutperform →Market PerformJul 21, 2026
Morgan StanleymaintainOverweightJul 8, 2026

Earnings History

Next report: Feb 9, 2027 · EPS est. $1.39
Report DateEPS ActualEPS Est.Revenue ActualRevenue Est.
Oct 29, 2026$2.55$2.19$8.30B$7.81B
Aug 4, 2026$-6.75$-7.25$7.80B$7.40B
May 7, 2026$2.03$1.91$6.96B$6.91B
Feb 10, 2026$1.86$1.81$7.92B$7.69B
Oct 30, 2025$2.47$2.13$7.77B$7.45B
Aug 7, 2025$2.01$1.96$7.08B$6.98B
Apr 24, 2025$1.81$1.78$6.67B$6.81B
Feb 11, 2025$1.90$1.74$7.57B$7.15B

News

The Top 5 Biotech Stocks I'd Buy Right Now Without Any Hesitation

These are among the best the industry has to offer.

Nov 8, 2026fool.com
Gilead Pays a $3.28 Annual Dividend Despite Negative Earnings. Is It Safe?

A red ink EPS figure usually spells trouble for retirees counting on a payout. Gilead's loss traces back to one strange quarter, and a single cash metric reveals whether the dividend checks are really at risk.

Nov 7, 2026247wallst.com
Positive Phase 3 IDEAL Study Results Further Support Livdelzi®'s (Seladelpar) Impact on Achieving ALP Normalization Goals in Second-Line Treatment Across a Broad Population of People Living with Primary Biliary Cholangitis (PBC)

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the detailed results from the Phase 3 IDEAL study, which demonstrated that the majority of participants living with PBC and treated with Livdelzi® (seladelpar) achieved the alkaline phosphatase (ALP) normalization composite endpoint defined as a composite of ALP ≤ 1.0× upper limit of normal (ULN) and a ≥ 15% decrease from baseline. ALP is a key marker of disease activity and long-term outcomes in PBC. The.

Nov 5, 2026businesswire.com
Gilead Sciences Has Raised Its Dividend for 11 Straight Years. Here's Why the Streak Looks Safe.

Gilead's HIV therapies generate strong free cash flow. The company is successfully branching out into oncology and anti-inflammatory therapies.

Nov 5, 2026fool.com
Ascent Group LLC Sells 7,256 Shares of Gilead Sciences, Inc. $GILD

Ascent Group LLC cut its stake in Gilead Sciences, Inc. (NASDAQ: GILD) by 11.5% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 56,100 shares of the biopharmaceutical company's stock after selling 7,256 shares during the quarter. Ascent Group LLC's holdings

Nov 5, 2026defenseworld.net
Gilead Sciences (NASDAQ:GILD) Stock Sees Unusually High Put Option Buying

Gilead Sciences, Inc. (NASDAQ: GILD - Get Free Report) was the recipient of unusually large options trading activity on Tuesday. Stock investors acquired 16,499 put options on the stock. This is an increase of 107% compared to the average volume of 7,952 put options. Gilead Sciences Trading Up 4.2% Shares of Gilead Sciences stock opened at

Nov 5, 2026defenseworld.net
Gilead Sciences, Inc. (GILD) Is a Trending Stock: Facts to Know Before Betting on It

Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Nov 4, 2026zacks.com
Gilead and Kite Advance Leadership With New Data Across Pipeline and Portfolio at ASH 2026

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, today announced 23 presentations, including 7 oral presentations, will be presented at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition (December 12–15, 2026). These latest clinical milestones demonstrate transformative progress across Gilead and Kite's pipeline and portfolio, from new data for the investigational anitocabtagene autoleucel (anito-cel) in relapsed or.

Nov 4, 2026businesswire.com
Gilead to Present Late-Breaking Clinical Data and Real-World Evidence at HIV Glasgow

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) today announced its upcoming participation in the International Congress on Drug Therapy in HIV Infection (HIV Glasgow 2026), taking place from November 8-11. As a leader in HIV innovation, Gilead will share new clinical data and real-world evidence from its HIV research and development programs and provide updates on its strategic initiatives and key collaborations. Results from more than 50 studies, including la…

Nov 2, 2026businesswire.com
189,152 Gilead Sciences, Inc. $GILD Shares Purchased by Bank Julius Baer & Co. Ltd Zurich

Bank Julius Baer and Co. Ltd Zurich increased its position in Gilead Sciences, Inc. (NASDAQ: GILD) by 22.3% during the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 1,038,316 shares of the biopharmaceutical company's stock after buying an additional

Nov 2, 2026defenseworld.net
1 Dividend-Paying Biotech Stock to Buy Hand Over Fist in November

The company is having a great year.

Nov 1, 2026fool.com
Gilead Sciences to Present at Upcoming Fourth Quarter 2026 Investor Conferences

FOSTER CITY, Calif.--(BUSINESS WIRE)-- #GILD--Gilead Sciences, Inc. (Nasdaq: GILD) announced today that its executives will be speaking at the following investor conferences:Wolfe Research Healthcare Conference on Tuesday, November 10 at 11:20 AM Eastern TimeUBS Global Biopharma Conference on Tuesday, November 17 at 10:00 AM Greenwich Mean TimeJefferies Global Healthcare Conference on Tuesday, November 17 at 2:30 PM Greenwich Mean TimeCiti's Global Healthcare Conference on Tuesday, December 1 at…

Oct 30, 2026businesswire.com
Gilead: Q3 Earnings Overview - It's Time To Consider Selling After Stellar Year

Gilead Sciences, Inc. delivered its strongest growth in a decade, with Q3 revenues up 16% ex-Veklury and robust HIV franchise performance. GILD's HIV division remains dominant, but Biktarvy faces 2028 Medicare price controls, expected to reduce revenue by $1.5bn that year. Oncology and immunology franchises lag, with mixed M&A results and limited near-term growth outside HIV despite heavy investment.

Oct 30, 2026seekingalpha.com
GILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales Growth

Gilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.

Oct 30, 2026zacks.com
GILD Q3 Earnings Call Highlights Raised Outlook and Pricing Risks

Gilead Sciences, Inc. GILD raised its 2026 sales outlook following strong third-quarter growth while providing new details on a significant Biktarvy pricing headwind expected in 2028.

Oct 30, 2026zacks.com
Gilead: The Business Is Growing, But The Valuation No Longer Works

Gilead Sciences faces valuation headwinds despite strong Q3 results and successful HIV, Trodelvy, and Yeztugo growth. Medicare pricing will reduce Biktarvy revenue by $1.5 billion annually starting in 2028, intensifying GILD's dependence on HIV. Q3 HIV growth was inflated by inventory build and a favorable channel mix, making it unsustainable for future quarters.

Oct 30, 2026seekingalpha.com
Gilead Sciences: Why I Remain Bullish After Q3

Gilead Sciences had a strong Q3. Sales of Trodelvy, a Trop-2-directed antibody-drug conjugate approved for the treatment of breast cancer, were $506 million, up 41.7% YoY and 10.7% QoQ. On October 22, Gilead agreed to acquire PepStar's oral IL-23R inhibitor program, including HCXT-2001, for $1.275 billion upfront.

Oct 30, 2026seekingalpha.com
These Analysts Increase Their Forecasts On Gilead Sciences After Upbeat Q3 Results

Gilead Sciences, Inc. (NASDAQ:GILD) reported better-than-expected earnings for the third quarter on Thursday.

Oct 30, 2026benzinga.com
Gilead Sciences, Inc. (GILD) Q3 2026 Earnings Call Transcript

Gilead Sciences, Inc. ( GILD ) Q3 2026 Earnings Call October 29, 2026 4:30 PM EDT Company Participants Jacquie Ross - Senior Vice President of Treasury & Investor Relations Daniel O'Day - Chairman & CEO Johanna Mercier - Chief Commercial & Corporate Affairs Officer Dietmar Berger - Chief Medical Officer Andrew Dickinson - Executive VP & CFO Cindy Perettie - Executive Vice President of Kite Conference Call Participants Umer Raffat - Evercore ISI Institutional Equities, Research Division Akash Tew…

Oct 30, 2026seekingalpha.com
Gilead (GILD) Q3 Earnings: Taking a Look at Key Metrics Versus Estimates

The headline numbers for Gilead (GILD) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Oct 29, 2026zacks.com